ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,443.86
0.23%
Dow Jones
38,613.00
0.06%
US Dollar vs MXN
18.49907
0.15%
Brent Oil
83.035
1.11%
Bitcoin
65,453.29
-1.78%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Cadrenal Therapeutics Inc (CVKD)

  7. Cadrenal Therapeutics Inc (CVKD) Noticias

CVKD

Cadrenal Therapeutics (CVKD)

Cadrenal Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:CVKD
FechaHoraFuenteTítuloSímboloCompañía
12/06/202415:10Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CVKDCadrenal Therapeutics Inc
11/06/202416:27Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:CVKDCadrenal Therapeutics Inc
11/06/202416:25Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CVKDCadrenal Therapeutics Inc
03/06/202408:00PR Newswire (US)Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD PatientsNASDAQ:CVKDCadrenal Therapeutics Inc
29/05/202416:27Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:CVKDCadrenal Therapeutics Inc
23/05/202408:00PR Newswire (US)Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024NASDAQ:CVKDCadrenal Therapeutics Inc
09/05/202408:00PR Newswire (US)Cadrenal Therapeutics Provides First Quarter 2024 Corporate UpdateNASDAQ:CVKDCadrenal Therapeutics Inc
09/05/202405:23Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CVKDCadrenal Therapeutics Inc
11/04/202415:30PR Newswire (US)Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024NASDAQ:CVKDCadrenal Therapeutics Inc
09/04/202408:00PR Newswire (US)Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial HeartsNASDAQ:CVKDCadrenal Therapeutics Inc
11/03/202408:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CVKDCadrenal Therapeutics Inc
11/03/202408:00PR Newswire (US)Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate UpdateNASDAQ:CVKDCadrenal Therapeutics Inc
26/02/202408:00PR Newswire (US)Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) ConferenceNASDAQ:CVKDCadrenal Therapeutics Inc
15/02/202407:00Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:CVKDCadrenal Therapeutics Inc
08/02/202408:00PR Newswire (US)Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal TrialNASDAQ:CVKDCadrenal Therapeutics Inc
31/01/202408:00PR Newswire (US)Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical ConditionsNASDAQ:CVKDCadrenal Therapeutics Inc
24/01/202408:00PR Newswire (US)Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024NASDAQ:CVKDCadrenal Therapeutics Inc
04/01/202408:00PR Newswire (US)Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare ConferenceNASDAQ:CVKDCadrenal Therapeutics Inc
19/12/202308:00PR Newswire (US)Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price TargetNASDAQ:CVKDCadrenal Therapeutics Inc
12/12/202308:00PR Newswire (US)Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and CommercializationNASDAQ:CVKDCadrenal Therapeutics Inc
30/11/202315:15PR Newswire (US)Cadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023NASDAQ:CVKDCadrenal Therapeutics Inc
09/11/202308:00PR Newswire (US)Cadrenal Therapeutics Provides Third Quarter 2023 Corporate UpdateNASDAQ:CVKDCadrenal Therapeutics Inc
09/10/202315:15PR Newswire (US)Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2023 Investor ConferenceNASDAQ:CVKDCadrenal Therapeutics Inc
05/09/202307:00PR Newswire (US)Cadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist (Tecarfarin) Following Updates from the Recent European Society of Cardiology CongressNASDAQ:CVKDCadrenal Therapeutics Inc
30/08/202307:00PR Newswire (US)Cadrenal Therapeutics Expands Evaluation of Tecarfarin for Patients with Antiphospholipid Syndrome (APS)NASDAQ:CVKDCadrenal Therapeutics Inc
28/08/202315:15PR Newswire (US)Cadrenal Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:CVKDCadrenal Therapeutics Inc
16/08/202315:05Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:CVKDCadrenal Therapeutics Inc
10/08/202308:00PR Newswire (US)Cadrenal Therapeutics Provides Second Quarter 2023 Corporate UpdateNASDAQ:CVKDCadrenal Therapeutics Inc
01/08/202308:00PR Newswire (US)Cadrenal Therapeutics Expands Focus for Tecarfarin to Patients with Implanted Medical Devices for Heart DiseasesNASDAQ:CVKDCadrenal Therapeutics Inc
30/07/202323:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CVKDCadrenal Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CVKD

Su Consulta Reciente

NASDAQ
GOOGL
Alphabet
USOTC
ADDYY
Adidas (QX)
NASDAQ
NVDA
NVIDIA
NYSE
KO
Coca Cola
USOTC
RHHBY
Roche (QX)
PM
XAUUSD
Gold vs US Dollar
COIN
SOLUSD
Solana
NYSE
NKE
Nike
USOTC
BNPQY
BNP Paribas (QX)
AMEX
SPY
SPDR S&P 500
NYSE
AXP
American Express
FX
USDMXN
US Dollar vs MXN
NASDAQ
MSFT
Microsoft
NYSE
JPM
JP Morgan Chase
USOTC
BASFY
BASF (QX)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados